---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-075757"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-07-07T12:05:25+00:00"
generated_at: "2026-07-07T12:10:14.881069+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial

## Summary
- Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.
- Final Stage 2 design will enroll 120-135 patients across full EASI spectrum (≥1.1) using Hochberg multiple testing procedure for four endpoints.
- GX-03 demonstrated favorable safety with no treatment-related serious adverse events or discontinuations reported.
- Company expects to complete enrollment in Q4 2026 and is capitalized through Q3 2027.
- Turn Therapeutics hosted an investor webcast on July 7, 2026 at 4:30 PM ET to discuss the results.

## SEC filing metadata
- accession: 0001213900-26-075757
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-07-07T12:05:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/0001213900-26-075757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/ea0297061-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-075757
- JSON: https://secwatch.observer/filing/0001213900-26-075757.json
- Plain text: https://secwatch.observer/filing/0001213900-26-075757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.